Loading asset research
Q3 2026 earnings · Sep 17
Chemomab Therapeutics Ltd. American Depositary Share
CMMBNasdaq · USD · StocksQuote as of · Exchange session not verified$2.58
-0.77%
Today
CMMB
Loading 1D prices…
Market cap
$18.9M
Volume
100.7K
52w high
$3.5852w low
$1.35Company profile
Chemomab Therapeutics Ltd. American Depositary Share
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Tel Aviv-Yafo, United States
Fiscal year end
1231
CIK
1534248
Session & valuation
Open$2.66
Previous close$2.60
Day high$2.76
Day low$2.56
30-day avg. volume94.8K
Outstanding shares575.4M
Diluted EPS$0.018
Latest annual period
P/E (trailing)143.33
P/E (forward)-86.00
Price / book2.15
Beta0.76
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| NCELNewcelX Ltd. Ordinary Shares | $19.1M | $0.00 | — | $2.16 | -2.23% | Unrated |
| LPCNLipocine Inc. Common Stock | $18.7M | $2M | -487.18% | -$1.69 | +0.89% | Hold |
| MRKRMarker Therapeutics Inc. Common Stock | $19.2M | $0.00 | — | -$0.79 | -4.17% | Buy |
| ALLRAllarity Therapeutics Inc. Common Stock | $19.4M | $320K | -3509.69% | -$0.78 | -2.40% | Hold |
| NEUPNeuphoria Therapeutics Inc. Common Stock | $20.2M | $15.6M | -54.62% | -$2.11 | +0.67% | Hold |